What impact does the extension for implementing revised Schedule M of Drugs and Cosmetics Act have on pharma units

1. The 12-month extension for implementing the revised Schedule M of the Drugs and Cosmetics Act allows pharmaceutical units more time to comply with the new requirements. 2. This extension can help pharma units avoid potential punitive actions for non-compliance. 3. It provides an opportunity for pharmaceutical companies to make necessary changes to their manufacturing processes, infrastructure, and quality control systems. 4. The extension may lead to increased costs associated with upgrading facilities and training employees to meet the revised standards. 5. Overall, the extension offers a grace period for pharma units to ensure they meet the regulatory requirements without facing immediate repercussions.